Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours Article Swipe
Petri Bono
,
Christophe Massard
,
Katriina Peltola
,
Analía Azaro
,
Antoîne Italiano
,
Rebecca Kristeleit
,
Giuseppe Curigliano
,
Ulrik Lassen
,
Hendrik-Tobias Arkenau
,
Pasi Hakulinen
,
Chris Garratt
,
Tarja Ikonen
,
Mika Mustonen
,
Jordi Rodón
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1136/esmoopen-2020-001081
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1136/esmoopen-2020-001081
Related Topics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1136/esmoopen-2020-001081
- https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdf
- OA Status
- gold
- Cited By
- 8
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3108175435
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3108175435Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1136/esmoopen-2020-001081Digital Object Identifier
- Title
-
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumoursWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-01-01Full publication date if available
- Authors
-
Petri Bono, Christophe Massard, Katriina Peltola, Analía Azaro, Antoîne Italiano, Rebecca Kristeleit, Giuseppe Curigliano, Ulrik Lassen, Hendrik-Tobias Arkenau, Pasi Hakulinen, Chris Garratt, Tarja Ikonen, Mika Mustonen, Jordi RodónList of authors in order
- Landing page
-
https://doi.org/10.1136/esmoopen-2020-001081Publisher landing page
- PDF URL
-
https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdfDirect OA link when available
- Concepts
-
Dosing, Medicine, Phase (matter), Internal medicine, Oncology, Chemistry, Organic chemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
8Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 2, 2022: 5Per-year citation counts (last 5 years)
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3108175435 |
|---|---|
| doi | https://doi.org/10.1136/esmoopen-2020-001081 |
| ids.doi | https://doi.org/10.1136/esmoopen-2020-001081 |
| ids.mag | 3108175435 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33262202 |
| ids.openalex | https://openalex.org/W3108175435 |
| fwci | 0.77295483 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000368 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Aged |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D020533 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Angiogenesis Inhibitors |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D005260 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Female |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D006801 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Humans |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D008297 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Male |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D008875 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Middle Aged |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D009362 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Neoplasm Metastasis |
| mesh[7].qualifier_ui | Q000188 |
| mesh[7].descriptor_ui | D009369 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | drug therapy |
| mesh[7].descriptor_name | Neoplasms |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D047428 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Protein Kinase Inhibitors |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D017468 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Receptors, Fibroblast Growth Factor |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D042461 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000368 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Aged |
| mesh[12].qualifier_ui | Q000627 |
| mesh[12].descriptor_ui | D020533 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | therapeutic use |
| mesh[12].descriptor_name | Angiogenesis Inhibitors |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D005260 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Female |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D006801 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Humans |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D008297 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Male |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D008875 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Middle Aged |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D009362 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Neoplasm Metastasis |
| mesh[18].qualifier_ui | Q000188 |
| mesh[18].descriptor_ui | D009369 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | drug therapy |
| mesh[18].descriptor_name | Neoplasms |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D047428 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Protein Kinase Inhibitors |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D017468 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Receptors, Fibroblast Growth Factor |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D042461 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Vascular Endothelial Growth Factor A |
| type | article |
| title | Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours |
| biblio.issue | 6 |
| biblio.volume | 5 |
| biblio.last_page | e001081 |
| biblio.first_page | e001081 |
| topics[0].id | https://openalex.org/T10543 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9984999895095825 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Prostate Cancer Treatment and Research |
| topics[1].id | https://openalex.org/T10631 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9966999888420105 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1306 |
| topics[1].subfield.display_name | Cancer Research |
| topics[1].display_name | Cancer, Hypoxia, and Metabolism |
| topics[2].id | https://openalex.org/T10358 |
| topics[2].field.id | https://openalex.org/fields/31 |
| topics[2].field.display_name | Physics and Astronomy |
| topics[2].score | 0.9965000152587891 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/3108 |
| topics[2].subfield.display_name | Radiation |
| topics[2].display_name | Advanced Radiotherapy Techniques |
| is_xpac | False |
| apc_list.value | 2750 |
| apc_list.currency | EUR |
| apc_list.value_usd | 2965 |
| apc_paid.value | 2750 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 2965 |
| concepts[0].id | https://openalex.org/C2777288759 |
| concepts[0].level | 2 |
| concepts[0].score | 0.868510365486145 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q4164182 |
| concepts[0].display_name | Dosing |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6105051636695862 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C44280652 |
| concepts[2].level | 2 |
| concepts[2].score | 0.48060914874076843 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q104837 |
| concepts[2].display_name | Phase (matter) |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.3695392608642578 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.3462923467159271 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C185592680 |
| concepts[5].level | 0 |
| concepts[5].score | 0.13979291915893555 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[5].display_name | Chemistry |
| concepts[6].id | https://openalex.org/C178790620 |
| concepts[6].level | 1 |
| concepts[6].score | 0.0 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[6].display_name | Organic chemistry |
| keywords[0].id | https://openalex.org/keywords/dosing |
| keywords[0].score | 0.868510365486145 |
| keywords[0].display_name | Dosing |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.6105051636695862 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/phase |
| keywords[2].score | 0.48060914874076843 |
| keywords[2].display_name | Phase (matter) |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.3695392608642578 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.3462923467159271 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/chemistry |
| keywords[5].score | 0.13979291915893555 |
| keywords[5].display_name | Chemistry |
| language | en |
| locations[0].id | doi:10.1136/esmoopen-2020-001081 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210217024 |
| locations[0].source.issn | 2059-7029 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2059-7029 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | ESMO Open |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | |
| locations[0].pdf_url | https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | ESMO Open |
| locations[0].landing_page_url | https://doi.org/10.1136/esmoopen-2020-001081 |
| locations[1].id | pmid:33262202 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | ESMO open |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33262202 |
| locations[2].id | pmh:oai:air.unimi.it:2434/824926 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400516 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) |
| locations[2].source.host_organization | https://openalex.org/I189158943 |
| locations[2].source.host_organization_name | University of Milan |
| locations[2].source.host_organization_lineage | https://openalex.org/I189158943 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | http://hdl.handle.net/2434/824926 |
| locations[3].id | pmh:oai:doaj.org/article:37210da0f0874e5b851261086f8e9984 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | cc-by-sa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | ESMO Open, Vol 5, Iss 6 (2020) |
| locations[3].landing_page_url | https://doaj.org/article/37210da0f0874e5b851261086f8e9984 |
| locations[4].id | pmh:oai:pubmedcentral.nih.gov:7709506 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S2764455111 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | PubMed Central |
| locations[4].source.host_organization | https://openalex.org/I1299303238 |
| locations[4].source.host_organization_name | National Institutes of Health |
| locations[4].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[4].license | |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | ESMO Open |
| locations[4].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7709506 |
| locations[5].id | pmh:oai:helda.helsinki.fi:10138/324382 |
| locations[5].is_oa | False |
| locations[5].source.id | https://openalex.org/S4306401476 |
| locations[5].source.issn | |
| locations[5].source.type | repository |
| locations[5].source.is_oa | False |
| locations[5].source.issn_l | |
| locations[5].source.is_core | False |
| locations[5].source.is_in_doaj | False |
| locations[5].source.display_name | Helda (University of Helsinki) |
| locations[5].source.host_organization | https://openalex.org/I133731052 |
| locations[5].source.host_organization_name | University of Helsinki |
| locations[5].source.host_organization_lineage | https://openalex.org/I133731052 |
| locations[5].license | |
| locations[5].pdf_url | |
| locations[5].version | submittedVersion |
| locations[5].raw_type | Article |
| locations[5].license_id | |
| locations[5].is_accepted | False |
| locations[5].is_published | False |
| locations[5].raw_source_name | |
| locations[5].landing_page_url | http://hdl.handle.net/10138/324382 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5006874570 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3963-0416 |
| authorships[0].author.display_name | Petri Bono |
| authorships[0].countries | FI |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2800394112 |
| authorships[0].affiliations[0].raw_affiliation_string | Comprehensive Cancer Centre, Helsinki University Central Hospital, Helsinki, Finland |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I133731052 |
| authorships[0].affiliations[1].raw_affiliation_string | Faculty of Medicine, University of Helsinki, Helsinki, Finland |
| authorships[0].institutions[0].id | https://openalex.org/I2800394112 |
| authorships[0].institutions[0].ror | https://ror.org/02e8hzf44 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2800394112, https://openalex.org/I4210166427 |
| authorships[0].institutions[0].country_code | FI |
| authorships[0].institutions[0].display_name | Helsinki University Hospital |
| authorships[0].institutions[1].id | https://openalex.org/I133731052 |
| authorships[0].institutions[1].ror | https://ror.org/040af2s02 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I133731052 |
| authorships[0].institutions[1].country_code | FI |
| authorships[0].institutions[1].display_name | University of Helsinki |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Petri Bono |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Comprehensive Cancer Centre, Helsinki University Central Hospital, Helsinki, Finland, Faculty of Medicine, University of Helsinki, Helsinki, Finland |
| authorships[1].author.id | https://openalex.org/A5090082356 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-5505-0564 |
| authorships[1].author.display_name | Christophe Massard |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2801843802 |
| authorships[1].affiliations[0].raw_affiliation_string | Cancer Centre, Drug Development Department, DITEP, Gustave Roussy, Villejuif, France |
| authorships[1].institutions[0].id | https://openalex.org/I2801843802 |
| authorships[1].institutions[0].ror | https://ror.org/0321g0743 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I2801843802 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Institut Gustave Roussy |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Christophe Massard |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Cancer Centre, Drug Development Department, DITEP, Gustave Roussy, Villejuif, France |
| authorships[2].author.id | https://openalex.org/A5011563007 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3007-193X |
| authorships[2].author.display_name | Katriina Peltola |
| authorships[2].countries | FI |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2800394112 |
| authorships[2].affiliations[0].raw_affiliation_string | Comprehensive Cancer Centre, Helsinki University Central Hospital, Helsinki, Finland |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I133731052 |
| authorships[2].affiliations[1].raw_affiliation_string | Faculty of Medicine, University of Helsinki, Helsinki, Finland |
| authorships[2].institutions[0].id | https://openalex.org/I2800394112 |
| authorships[2].institutions[0].ror | https://ror.org/02e8hzf44 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2800394112, https://openalex.org/I4210166427 |
| authorships[2].institutions[0].country_code | FI |
| authorships[2].institutions[0].display_name | Helsinki University Hospital |
| authorships[2].institutions[1].id | https://openalex.org/I133731052 |
| authorships[2].institutions[1].ror | https://ror.org/040af2s02 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I133731052 |
| authorships[2].institutions[1].country_code | FI |
| authorships[2].institutions[1].display_name | University of Helsinki |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Katriina J. Peltola |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Comprehensive Cancer Centre, Helsinki University Central Hospital, Helsinki, Finland, Faculty of Medicine, University of Helsinki, Helsinki, Finland |
| authorships[3].author.id | https://openalex.org/A5112385468 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Analía Azaro |
| authorships[3].countries | ES |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210127641 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain |
| authorships[3].institutions[0].id | https://openalex.org/I4210127641 |
| authorships[3].institutions[0].ror | https://ror.org/03ba28x55 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210127641 |
| authorships[3].institutions[0].country_code | ES |
| authorships[3].institutions[0].display_name | Vall d'Hebron Hospital Universitari |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Analía Azaro |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain |
| authorships[4].author.id | https://openalex.org/A5060949051 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-8540-5351 |
| authorships[4].author.display_name | Antoîne Italiano |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I15057530 |
| authorships[4].affiliations[0].raw_affiliation_string | Faculty of Medicine, University of Bordeaux, Talence, France |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I4210134409 |
| authorships[4].affiliations[1].raw_affiliation_string | Early Phase Trials Unit, Institut Bergonié, Bordeaux, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210134409 |
| authorships[4].institutions[0].ror | https://ror.org/02yw1f353 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210134409 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Institut Bergonié |
| authorships[4].institutions[1].id | https://openalex.org/I15057530 |
| authorships[4].institutions[1].ror | https://ror.org/057qpr032 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I15057530 |
| authorships[4].institutions[1].country_code | FR |
| authorships[4].institutions[1].display_name | Université de Bordeaux |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Antoine Italiano |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Early Phase Trials Unit, Institut Bergonié, Bordeaux, France, Faculty of Medicine, University of Bordeaux, Talence, France |
| authorships[5].author.id | https://openalex.org/A5088144652 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-3825-1326 |
| authorships[5].author.display_name | Rebecca Kristeleit |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210088881, https://openalex.org/I45129253 |
| authorships[5].affiliations[0].raw_affiliation_string | Research Department of Oncology, University College London Cancer Institute, London, UK |
| authorships[5].institutions[0].id | https://openalex.org/I4210088881 |
| authorships[5].institutions[0].ror | https://ror.org/005kpb876 |
| authorships[5].institutions[0].type | other |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210088881 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | London Cancer |
| authorships[5].institutions[1].id | https://openalex.org/I45129253 |
| authorships[5].institutions[1].ror | https://ror.org/02jx3x895 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I124357947, https://openalex.org/I45129253 |
| authorships[5].institutions[1].country_code | GB |
| authorships[5].institutions[1].display_name | University College London |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Rebecca S. Kristeleit |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Research Department of Oncology, University College London Cancer Institute, London, UK |
| authorships[6].author.id | https://openalex.org/A5003897511 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-1781-2518 |
| authorships[6].author.display_name | Giuseppe Curigliano |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I6141010 |
| authorships[6].affiliations[0].raw_affiliation_string | Division of Early Drug Development, IRCCS, European Institute of Oncology, Milano, Italy |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I189158943 |
| authorships[6].affiliations[1].raw_affiliation_string | University of Milan, Milano, Italy |
| authorships[6].institutions[0].id | https://openalex.org/I6141010 |
| authorships[6].institutions[0].ror | https://ror.org/02vr0ne26 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210153126, https://openalex.org/I6141010 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | European Institute of Oncology |
| authorships[6].institutions[1].id | https://openalex.org/I189158943 |
| authorships[6].institutions[1].ror | https://ror.org/00wjc7c48 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I189158943 |
| authorships[6].institutions[1].country_code | IT |
| authorships[6].institutions[1].display_name | University of Milan |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Giuseppe Curigliano |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Division of Early Drug Development, IRCCS, European Institute of Oncology, Milano, Italy, University of Milan, Milano, Italy |
| authorships[7].author.id | https://openalex.org/A5077199450 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-3865-4574 |
| authorships[7].author.display_name | Ulrik Lassen |
| authorships[7].countries | DK |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I124055696 |
| authorships[7].affiliations[0].raw_affiliation_string | University of Copenhagen, Kobenhavn, Denmark |
| authorships[7].affiliations[1].institution_ids | https://openalex.org/I2802709434 |
| authorships[7].affiliations[1].raw_affiliation_string | Department of Oncology, Rigshospitalet, Kobenhavn, Denmark |
| authorships[7].institutions[0].id | https://openalex.org/I2802709434 |
| authorships[7].institutions[0].ror | https://ror.org/03mchdq19 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2802567020, https://openalex.org/I2802709434, https://openalex.org/I4210145385 |
| authorships[7].institutions[0].country_code | DK |
| authorships[7].institutions[0].display_name | Rigshospitalet |
| authorships[7].institutions[1].id | https://openalex.org/I124055696 |
| authorships[7].institutions[1].ror | https://ror.org/035b05819 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I124055696 |
| authorships[7].institutions[1].country_code | DK |
| authorships[7].institutions[1].display_name | University of Copenhagen |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Ulrik Lassen |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Oncology, Rigshospitalet, Kobenhavn, Denmark, University of Copenhagen, Kobenhavn, Denmark |
| authorships[8].author.id | https://openalex.org/A5112421112 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Hendrik-Tobias Arkenau |
| authorships[8].countries | GB |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I172427033 |
| authorships[8].affiliations[0].raw_affiliation_string | Sarah Cannon Research Institute, London, UK |
| authorships[8].institutions[0].id | https://openalex.org/I172427033 |
| authorships[8].institutions[0].ror | https://ror.org/03cp5cj42 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I172427033 |
| authorships[8].institutions[0].country_code | GB |
| authorships[8].institutions[0].display_name | Sarah Cannon Research Institute |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Hendrik-Tobias Arkenau |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Sarah Cannon Research Institute, London, UK |
| authorships[9].author.id | https://openalex.org/A5028425176 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-2514-6842 |
| authorships[9].author.display_name | Pasi Hakulinen |
| authorships[9].countries | FI |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210118237 |
| authorships[9].affiliations[0].raw_affiliation_string | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[9].institutions[0].id | https://openalex.org/I4210118237 |
| authorships[9].institutions[0].ror | https://ror.org/0296s4x19 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210118237 |
| authorships[9].institutions[0].country_code | FI |
| authorships[9].institutions[0].display_name | Orion Corporation (Finland) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Pasi Hakulinen |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[10].author.id | https://openalex.org/A5063718926 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-2137-1017 |
| authorships[10].author.display_name | Chris Garratt |
| authorships[10].countries | FI |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210118237 |
| authorships[10].affiliations[0].raw_affiliation_string | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[10].institutions[0].id | https://openalex.org/I4210118237 |
| authorships[10].institutions[0].ror | https://ror.org/0296s4x19 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210118237 |
| authorships[10].institutions[0].country_code | FI |
| authorships[10].institutions[0].display_name | Orion Corporation (Finland) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Chris Garratt |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[11].author.id | https://openalex.org/A5113636312 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Tarja Ikonen |
| authorships[11].countries | FI |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210118237 |
| authorships[11].affiliations[0].raw_affiliation_string | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[11].institutions[0].id | https://openalex.org/I4210118237 |
| authorships[11].institutions[0].ror | https://ror.org/0296s4x19 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210118237 |
| authorships[11].institutions[0].country_code | FI |
| authorships[11].institutions[0].display_name | Orion Corporation (Finland) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Tarja Ikonen |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[12].author.id | https://openalex.org/A5021509081 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-7899-0564 |
| authorships[12].author.display_name | Mika Mustonen |
| authorships[12].countries | FI |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210118237 |
| authorships[12].affiliations[0].raw_affiliation_string | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[12].institutions[0].id | https://openalex.org/I4210118237 |
| authorships[12].institutions[0].ror | https://ror.org/0296s4x19 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210118237 |
| authorships[12].institutions[0].country_code | FI |
| authorships[12].institutions[0].display_name | Orion Corporation (Finland) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Mika V.J. Mustonen |
| authorships[12].is_corresponding | True |
| authorships[12].raw_affiliation_strings | Research and Development, Orion Corporation, Espoo, Finland |
| authorships[13].author.id | https://openalex.org/A5031165814 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-6467-3632 |
| authorships[13].author.display_name | Jordi Rodón |
| authorships[13].countries | ES |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210127641 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain |
| authorships[13].institutions[0].id | https://openalex.org/I4210127641 |
| authorships[13].institutions[0].ror | https://ror.org/03ba28x55 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210127641 |
| authorships[13].institutions[0].country_code | ES |
| authorships[13].institutions[0].display_name | Vall d'Hebron Hospital Universitari |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Jordi A. Rodon |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10543 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9984999895095825 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Prostate Cancer Treatment and Research |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W1489783725 |
| cited_by_count | 8 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2022 |
| counts_by_year[2].cited_by_count | 5 |
| locations_count | 6 |
| best_oa_location.id | doi:10.1136/esmoopen-2020-001081 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210217024 |
| best_oa_location.source.issn | 2059-7029 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2059-7029 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | ESMO Open |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | ESMO Open |
| best_oa_location.landing_page_url | https://doi.org/10.1136/esmoopen-2020-001081 |
| primary_location.id | doi:10.1136/esmoopen-2020-001081 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210217024 |
| primary_location.source.issn | 2059-7029 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2059-7029 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | ESMO Open |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | |
| primary_location.pdf_url | https://esmoopen.bmj.com/content/esmoopen/5/6/e001081.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | ESMO Open |
| primary_location.landing_page_url | https://doi.org/10.1136/esmoopen-2020-001081 |
| publication_date | 2020-01-01 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2797795705, https://openalex.org/W2777339059, https://openalex.org/W2100374586, https://openalex.org/W1505632988, https://openalex.org/W2595713273, https://openalex.org/W2161608625, https://openalex.org/W2626344037, https://openalex.org/W1964015222, https://openalex.org/W2082407856, https://openalex.org/W2762965865, https://openalex.org/W2118155696, https://openalex.org/W2275670662, https://openalex.org/W1986779513, https://openalex.org/W167047041, https://openalex.org/W1038585844, https://openalex.org/W2898174432, https://openalex.org/W2897182820, https://openalex.org/W2096735709, https://openalex.org/W2623751690, https://openalex.org/W2020709543, https://openalex.org/W1993881314, https://openalex.org/W2964014383 |
| referenced_works_count | 22 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5021509081 |
| countries_distinct_count | 6 |
| institutions_distinct_count | 14 |
| corresponding_institution_ids | https://openalex.org/I4210118237 |
| citation_normalized_percentile.value | 0.74322805 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |